Ischemia Reperfusion Injury Therapeutics Market Will hit US$ 2,290.1 Million by 2027 | CAGR: 5.4%: Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The Global Ischemia-Reperfusion Injury Therapeutics Market, by Indication (Heart Injury, Kidney Injury, Intestine Injury, and Other Injury), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,582.3  million in 2020 and is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-sample/4105

There is no established treatment for ischemia-reperfusion injury till now. Being a niche and capital intensive therapy area, companies are collaborating in order to synergize their strengths and develop a treatment.

For instance, in May 2019, Abiomed received an FDA approval for its STEM DTU trial of delayed ischemic reperfusion injury. This clinical trial will test the hypothesis that unloading the left ventricle for 30 minutes before ischemia and reperfusion injury (IRI) to reduce myocardial damage from a heart attack and decrease in the heart failure-related events in future.

Browse 26 Market Data Tables and 28 Figures spread through 156 Pages and in-depth TOC on Ischemia-Reperfusion Injury Therapeutics Market, by Indication (Heart Injury, Kidney Injury, Intestine Injury, and Other Injury), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)– Forecast to 2027″

To know the latest trends and insights related to the Global Ischemia-Reperfusion Injury Therapeutics Market Press Release, click the link below: https://www.coherentmarketinsights.com/press-release/ischemia-reperfusion-injury-therapeutics-market-3364

In January 2020, a cannabis life sciences company, Revive Therapeutics Ltd., provided an update regarding its clinical development plan on liver diseases. The company’s aim is to expand its product pipeline by leveraging its U.S. Food and Drug Administration orphan drug designation for Cannabidiol for the prevention of ischemia and reperfusion injury from organ transplantation.

The emergence of drugs for treatment of complications related to ischemia-reperfusion and rising number of research & development activities are some of the factors driving growth of the global ischemia-reperfusion injury therapeutics. For instance, Faraday Pharmaceuticals in November 2019, announced phase II clinical trials’ positive top-line results of FDY-5301, for ischemia and reperfusion injury treatment.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/4105

Key Takeaways of the Global Ischemia Reperfusion Injury Therapeutics Market:

• The global ischemia-reperfusion injury therapeutics market is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027) owing to increasing research & development of novel therapies and treatments for ischemia and reperfusion injury.
• Among distribution channel, the hospital pharmacy segment is expected to hold the largest revenue share in the market in 2027 owing to the rising number of tissue damage cases and ischemia and reperfusion injury. This is mainly because ischemia-reperfusion injury is the tissue damage that arises when blood supply returns to the tissue (reperfusion) due to lack of oxygen (ischemia).
• Major players operating in the global ischemia-reperfusion injury therapeutics market are Omeros Corporation, Pharming Group N.V., Nyken B.V., Orexo AB, Opsona Therapeutics Limited, PledPharma AB, Prothix BV, Proteo, Inc., Amyndas Pharmaceuticals LLC, Prolong Pharmaceuticals, Stealth BioTherapeutics Inc., Zealand Pharma A/S, Antipodean Pharmaceuticals, Inc., Bayer AG, Angion Biomedica Corp., Bolder Biotechnology, Inc., Curatis Pharma GmbH, Biomedica Management Corporation, Ensemble Therapeutics Corporation, Gilead Sciences, Inc., and Erimos Pharmaceuticals, LLC.

Have a Look at Related Research Insights: